Understanding how common fatty liver disease is in patients with Type 1 Diabetes
Official title: The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
Run by Ziekenhuis Oost-Limburg · NCT06445361 · Data updated 2026-11-12
This study is trying to find out how many people with Type 1 Diabetes also have Nonalcoholic Fatty Liver Disease by using a special scan to check their liver health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 138 (estimated) |
| Sponsor | Ziekenhuis Oost-Limburg Academic / other |
| Locations | 1 site (Genk, Limburg) |
| Status | Recruiting |
| Started | July 1, 2023 |
| Main results expected | July 1, 2026 |
| Study ends | July 1, 2026 |
| Registry record updated | July 28, 2025 |
| Trial ID | NCT06445361 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a diagnosis of Type 1 Diabetes.
✕Probably not a fit
Patients with excessive alcohol use or other causes of liver disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) among patients diagnosed with Type 1 Diabetes Mellitus (T1DM). It involves the use of a FibroScan, a non-invasive imaging technique, to evaluate liver health in participants. The study will include adults aged 18 and older who provide informed consent, while excluding those with excessive alcohol use or other liver disease causes. The findings could provide valuable insights into the liver health of T1DM patients.
Why it matters
Potential benefit: If successful, this study could enhance understanding of liver health in Type 1 Diabetes patients, potentially leading to better management strategies.
How similar studies have gone: While studies on NAFLD in diabetes exist, this specific focus on T1DM patients is less common, making it a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * T1DM * ≥ 18 years of age * Written informed consent obtained Exclusion Criteria: * Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of liver steatosis
Where it's running
-
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium Recruiting
Study contacts
- Study coordinator: Leen Heyens, MsC
- Email: nafldstudie@zol.be
- Phone: 089 21 20 55
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity
This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.
-
Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes
This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.
-
CGM-guided carb awareness education for adults with Type 1 diabetes
This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.
-
Safety and effectiveness of GLP-1 receptor agonists and SGLT inhibitors added to insulin in adults with type 1 diabetes
This registry will see if adding GLP-1RA or SGLTi therapies to insulin helps adults with type 1 diabetes over one year.
-
Think-Find-Solve activities for insulin self-management in children with type 1 diabetes
A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.